Ancient Chinese Formula Logic Offers New Blueprint for Cancer Nutrition Therapy

Cancer does not only grow; it devours. One of the most underappreciated drivers of poor outcomes in oncology is the progressive nutritional collapse that many patients experience, a syndrome in which tumors and their treatments strip away muscle, drain energy reserves, and undermine the very therapies designed to defeat the disease. A newly published review in the journal Holistic Integrative Oncology argues that nutritional support should no longer be treated as an afterthought in cancer care, and it offers a strikingly fresh way to organize that support: by borrowing the architecture of a two-thousand-year-old Chinese medical prescription principle known as Jun-Chen-Zuo-Shi. The framework, proposed by Shenghao Lin, Bing Li, and Qinghua Yao, maps ancient prescription logic onto modern nutrient science, creating a hierarchy in which every nutrient has a defined role, from foundational energy provision to metabolic fine-tuning.

The scale of the problem the framework addresses is sobering. According to the ESPEN clinical nutrition guidelines cited in the review, tumor-induced metabolic disturbances and treatment-related toxicities contribute to malnutrition in a large proportion of patients, and an estimated 10 to 20 percent of people with cancer die from malnutrition rather than from the tumor itself. Recent meta-analyses report that severe malnutrition affects roughly 20 percent of cancer patients, with prevalence climbing to 46 percent among hospitalized patients assessed using the GLIM criteria. The consequences ripple across every dimension of care: a global multicenter study found that one third of patients undergoing gastrointestinal cancer surgery were severely malnourished, a condition linked to significantly higher 30-day postoperative mortality, while a separate meta-analysis showed that GLIM-defined malnutrition nearly triples the risk of death within one year compared with well-nourished patients.

The authors contend that the reason conventional nutritional support often falls short is structural rather than conceptual. Standard practice includes individualized dietary counseling, oral nutritional supplements, enteral nutrition, and parenteral nutrition, with the oral and enteral routes preferred whenever the gastrointestinal tract is functional. These interventions can improve intake, weight, and some patient-reported outcomes, but their effects vary widely depending on tumor type, baseline nutritional status, inflammatory burden, and treatment phase. Perioperative immunonutrition containing arginine, omega-3 fatty acids, and nucleotides has shown benefit in selected surgical populations, yet most existing strategies remain single-component or non-targeted. Cancer-associated wasting, by contrast, is a tangled web of metabolic reprogramming, systemic inflammation, immune dysfunction, gut-barrier injury, microbiota disturbance, and treatment toxicity, and no single nutrient can plausibly address all of these dimensions at once.

Enter the traditional Chinese medicine concept of prescription compatibility. In classical Chinese formularies, Jun herbs target the primary pathological mechanism, Chen herbs provide supportive and synergistic effects, Zuo herbs mitigate toxicity or moderate adverse effects, and Shi herbs guide the actions of the principal components and harmonize the whole formulation. The authors are careful to frame this as a translational metaphor rather than proof of pharmacological equivalence between herbs and nutrients. Still, they argue, the compatibility logic is unusually well suited to oncology nutrition because malnourished cancer patients often simultaneously face insufficient intake, inflammation, insulin resistance, skeletal muscle loss, mucosal injury, diarrhea, micronutrient deficiency, anxiety, and fatigue. A hierarchical structure helps clinicians distinguish non-negotiable foundations from optional adjuncts and prevents the substitution of essential energy and protein support with poorly evidenced supplements.

In the proposed model, Jun nutrients constitute the foundational substrate layer: proteins, carbohydrates, and fats. Protein is the centerpiece, with guidelines recommending at least 1.0 gram per kilogram of body weight per day in cancer patients, ideally raised to 1.2 to 1.5 grams per kilogram. Review evidence suggests that daily intake above 1.4 grams per kilogram during treatment helps preserve muscle mass, while intake below 1.2 grams is commonly associated with muscle loss. The PRIMe trial in colorectal cancer explored a high-protein intake of 2.0 grams per kilogram during chemotherapy, with preliminary findings suggesting that roughly half of the patients maintained or improved muscle mass. Carbohydrates serve as an efficient energy source that spares protein from oxidation, with complex carbohydrates and dietary fiber from whole grains, fruits, and vegetables improving insulin sensitivity and reducing inflammatory mediators, whereas refined sugars and high glycemic loads warrant caution given the Warburg effect and the possible association of hyperglycemia with tumor growth and invasion. Fats supply concentrated energy and essential fatty acids, with priority given to monounsaturated and polyunsaturated sources such as olive oil, nuts, and deep-sea fish oil. A randomized controlled trial showed that daily supplementation with six grams of medium-chain triglycerides improved muscle strength and daily functioning in frail older adults within three months, suggesting a potential role against cancer-related wasting, and Mediterranean-style, olive-oil-rich dietary patterns have been linked to substantially reduced breast cancer incidence.

Chen nutrients are the reinforcing layer, selected when a patient shows inflammation, muscle wasting, or impaired anabolic response. The prototype is the omega-3 polyunsaturated fatty acids EPA and DHA, which suppress pro-inflammatory eicosanoids and cytokines, inhibit nuclear factor-kappa B activation, and enhance insulin sensitivity. Clinical studies report that fish oil supplementation improves appetite, increases skeletal muscle mass, and stabilizes body weight in advanced cancer, and a meta-analysis found that oral supplements containing omega-3 fatty acids increased body weight in patients with cancer cachexia by an average of approximately 1.22 kilograms alongside significant improvements in quality-of-life scores. Branched-chain amino acids, particularly leucine, and its metabolite beta-hydroxy-beta-methylbutyrate, activate the mTOR pathway and suppress muscle protein breakdown, respectively. A meta-analysis in hepatocellular carcinoma showed that perioperative supplementation reduced postoperative infections and ascites and produced average weight gains of nearly two kilograms. L-carnitine completes this tier by transporting long-chain fatty acids into mitochondria, suppressing proteolysis through AKT and FOXO3a signaling, and, in early clinical work, improving fatigue, body composition, and quality of life in patients with advanced cancer.

Zuo nutrients act as coordinating adjuncts that protect the gut and buffer treatment toxicity. Probiotics such as Lactobacillus and Bifidobacterium species, together with prebiotics like inulin, support intestinal barrier function and short-chain fatty acid production. Systematic reviews indicate that probiotic use among patients receiving chemotherapy or radiotherapy reduces the risk of diarrhea of any grade by approximately 65 percent and severe diarrhea by about 57 percent, while another meta-analysis reported a roughly 30 percent reduction in chemotherapy-induced diarrhea and a halving of severe cases, alongside markedly lower rates of oral mucositis. Glutamine, a conditionally essential amino acid during physiological stress, fuels intestinal epithelial cells, promotes mucosal repair, and reduces permeability and bacterial translocation. Meta-analyses show that glutamine nearly halves the risk of grade III to IV oral mucositis from chemotherapy or radiotherapy, prompting MASCC to list oral glutamine as an optional prophylactic measure, and supplementation has also reduced chemotherapy-induced diarrhea in colorectal cancer patients by roughly 35 percent.

Shi nutrients, the guiding cofactors, include vitamins, trace elements, and coenzymes that make the entire system work. B vitamins drive energy metabolism and hematopoiesis, vitamins A, C, and E support epithelial integrity and antioxidant defense, and vitamin D carries endocrine and immunomodulatory functions, with higher serum levels associated with longer survival in patients receiving immune checkpoint inhibitors. Trace elements matter enormously: in a retrospective study of gynecological malignancies, serum zinc declined significantly after surgery and chemoradiotherapy, and zinc deficiency was 4.8 times more likely in patients whose tumors recurred, with levels below 61 micrograms per deciliter independently predicting recurrence. Iron, folate, and vitamin B12 are essential for erythropoiesis, though excessive iron must be avoided for its possible tumor-promoting effects. Coenzyme Q10, a mitochondrial electron carrier, has shown in breast cancer trials that 100 milligrams daily for six to twelve weeks significantly reduced circulating VEGF and IL-8 and suppressed matrix metalloproteinase activity, suggesting a possible role in easing fatigue and inflammation.

The framework’s greatest practical promise may lie in its adaptability to specific cancers and complications. In breast cancer, vitamin D and calcium anchor skeletal health during endocrine therapy while glutamine and probiotics buffer chemotherapy toxicity; in lung cancer, anti-inflammatory omega-3 fatty acids and branched-chain amino acids counter the cachexia that affects so many patients at diagnosis; in esophageal cancer, tube-fed enteral nutrition and perioperative immunonutrition with arginine and fish oil reduce postoperative infections; in hepatocellular carcinoma, branched-chain amino acid-enriched formulas meet protein needs while limiting ammonia-related metabolic burden. The authors stress that traditional Chinese medicine formulas, including Huangqi Sijunzi, Liujunzi, and Buzhong Yiqi decoctions, should complement rather than replace standard oncologic nutrition care, and they acknowledge that randomized controlled trials of structured nutrition-TCM integrative strategies remain limited. Looking ahead, they propose that patient stratification using metabolomics, inflammatory markers, and microbiome profiles, combined with nutritional informatics and systems modeling, could transform this ancient hierarchy into testable combination hypotheses and dosing rules, moving supportive oncology from experience-based practice toward genuinely data-driven, precision nutritional medicine.

Subject of Research: Application of the traditional Chinese medicine principle of Jun-Chen-Zuo-Shi to individualized nutritional therapy for cancer-associated malnutrition and cachexia.

Article Title: “Jun-Chen-Zuo-Shi” – the Chinese medical perspective on clinical oncology nutritional therapy

Article References: Lin, S., Li, B., & Yao, Q. (2026). “Jun-Chen-Zuo-Shi” – the Chinese medical perspective on clinical oncology nutritional therapy. Holistic Integrative Oncology, 5(1), Article 62. https://doi.org/10.1007/s44178-026-00282-9

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00282-9

Keywords: cancer cachexia, malnutrition, Jun-Chen-Zuo-Shi, traditional Chinese medicine, oncology nutrition, omega-3 fatty acids, branched-chain amino acids, glutamine, probiotics, micronutrients, nutritional therapy, lean body mass